Clinical Trials Flowcharts

May 2024
To refer a patient:

To learn more about a specific trial, contact the MOG leader listed, or call the clinical trials hotline.

All calls to the clinical trials hotline will be returned within 48 hours.

The clinical trials team will then work with you to get your patient enrolled, when appropriate.
# Table of Contents

- Breast
- GI
- GU
- Gynecologic
- Head & Neck
- Leukemia
- Lymphoma
- Melanoma
- Myeloma
- Myeloma
- Sarcoma
- Thoracic
- Cancer Services – Quad Cities
Breast Cancer Trials

Sneha Phadke, DO, MPH
Breast Cancer MOG Co-Leader
sneha-phadke@uiowa.edu

Mimi McKay, MPH, BSN
Clinical Trial Navigator
mariel-mckay@uiowa.edu

Clinical Trials Hotline: 319-353-8155
BREAST CANCER

ADJUVANT

HER 2+
- Astefania: Pathologic evidence of residual disease at surgery; received neoadjuvant chemo; less than 12 wk between surgery and randomization
  - NCT04873362
- Tropion: completed 6 cycles of neoadjuvant therapy w/ anthracycline and/or taxane; residual invasive disease in the breast or axillary LN at resection; no evidence of locoregional or distant relapse
  - NCT05629585

HER 2−
- TRIPLE NEGATIVE
  - Ascent05: Adequate excision and surgical removal of all clinical evidence of disease in the breast and/or LN and have adequately recovered from surgery
    - NCT05633654
  - Optim-ICE: T1cN1-2 or T2-4N0-2; no residual disease or LN after neoadjuvant therapy; neoadjuvant chemo+pembro x 6 cycles; < 12 weeks between surgery and randomization
    - NCT05812807

ER +
- RaPHLRR: Locoregional recurrence; adequate local treatment for locoregional recurrence; Enrolled within 6 mo of last local treatment
  - NCT05467891
- Cambria: must have had definitive locoregional therapy +/- adjuvant systemic therapy; completed at least 2 yrs (but no more than 5) of adjuvant ET (and is still receiving)
  - NCT05774951
- BR009: premenopausal; postoperative pT1-3; ipsilateral nodes pN0 or pN1; if node negative, oncotype DX RS 21-25 or 16-20 with high clinical risk disease; if 1-3 nodes+ oncotype DX RS 26
  - NCT05879926
**BREAST CANCER**

**METASTATIC TNBC**

- **Ascent03**: no prior systemic therapy for advanced disease unless PD-L1 + may have received CPI; must have completed treatment for stage I-III breast cancer if indicated and >6 mo have elapsed between curative intent treatment and documented recurrence

  - NCT05382299

- **OBT076-001**: A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors

  - NCT04064359
BREAST CANCER

METASTATIC HER2-

C4391022: ER+ and/or PR +; must have received CDK4/61 + NSAI with documented PD during or after CDK4/6i; measurable disease or non-measurable bone only disease as defined by RECIST1.1

NCT06105632

OBT076-001: A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors

NCT04064359

Olema: ER + and PR +/-; no more than 2 prior lines for metastatic disease; no more than 1 line of chemo for advanced/meta static disease

NCT05508906
BREAST CANCER

EARLY PHASE

P-MUC1C-ALLO1-001: A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors

NCT05239143

BGB-A317-A3055-101: A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors

NCT05935098
GI Cancer Trials

Chandrikha Chandrasekharan, MBBS
GI Cancer MOG Co-Leader
chandrikha-chandrasekharan@uiowa.edu

Mimi McKay, MPH, BSN
Clinical Trial Navigator
mariel-mckay@uiowa.edu

Clinical Trials Hotline: 319-353-8155
**PANCREATIC CANCER**

**ADJUVANT**

- **AMPLIFY7P**
  - Criteria: Up front resectable stage I, II, or III disease per current AJCC staging criteria, with radiographic NED (no evidence of disease) status within 6 months following completion of locoregional treatment
  - NCT05726864

**NON-RESECTABLE**

- **TIGER-PAC/RENOVO**
  - Criteria: Histo/cyto confirmed diagnosis within 6 weeks of consent; no prior treatment for pancreatic cancer OR more than 1 cycle of gem delivery and nab-paclitaxel; no evidence of metastatic disease; arterial anatomy suitable of intra-arterial of gemcitabine to intended tumor
  - NCT05249101

**METASTATIC**

- **CG-745-2-08**
  - Criteria: Locally advanced or metastatic pancreatic adenocarcinoma without evidence of progression on initial chemo for metastatic disease (CR, PR or SD); FOLFIRINOX at full or modified dose for a minimum of 16 wks with no evidence of progression
  - NCT05249101

- **P-MUC1C-ALLO1-001**
  - A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors
  - NCT:05249101

- **BGB-A317-A3055-101**
  - A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic s, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors
  - NCT05935098
COLORECTAL CANCER

**NEOADJUVANT**

**Dostarlimab**
Criteria: Biopsy proven Stage II or III dMMR amenable to en block surgical resection; biopsy specimen has enough tissue for 4-6 FFPE slides; absence of metastatic disease

NCT: 05239546

**ADJUVANT**

**NRG-GI008**
Criteria: T1-3, N1/N1c confirmed adenocarcinoma with RO resection; no radiographic evidence of overt metastatic disease; distal extent of tumor ≥12 cm from anal verge on colonoscopy or above peritoneal reflection as documented during surgery or on path specimen; must have had en bloc complete gross resection of tumor (curative resection); microsatellite stable or intact mismatch repair proteins through CLIA approved testing

NCT: 05174169

**METASTATIC**

**BXQ-350**
Criteria: Newly diagnosed stage IV metastatic adenocarcinoma of the colon/rectum; may not have mismatch repair deficiency or microsatellite instability status-high Stage IV colorectal cancer

NCT: 05322590

**BGB-A317-A3055-101**
Criteria: Pathologically documented, locally-advanced or metastatic malignancy with KRAS p.G12C mutation identified through molecular testing

NCT05935098

**KRAS G12c**

**CODEBREAK:**
Criteria: Pathologically documented, locally-advanced or metastatic malignancy with KRAS p.G12C mutation identified through molecular testing

NCT04185883

NCT: 05322590
GASTRIC CANCER

1L

A022102
Criteria: Unresectable or metastatic HER2-adenocarcinoma of esophagus, GEJ, or stomach; no prior treatment for unresectable or metastatic disease

NCT05677490

METASTATIC

BGB-A317-A3055-101: A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors

NCT05935098

OBT076-001: A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBTO76, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors

NCT04064359
GASTROESOPHAGEAL CANCER

A022102
Criteria: Unresectable or metastatic HER2-adenocarcinoma of esophagus, GEJ, or stomach; no prior treatment for unresectable or metastatic disease

NCT05677490

METASTATIC

OBT076-001: A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors

NCT04064359
GU Cancer Trials

Yousef Zakharia, MD
GU Cancer MOG Co-Leader
yousef-zakharia@uiowa.edu

Mimi McKay, MPH, BSN
Clinical Trial Navigator
mariel-mckay@uiowa.edu

Clinical Trials Hotline: 319-353-8155
**Bladder Cancer**

**NMIBC**
- **Adapt**
  - Criteria: Histologically confirmed urothelial carcinoma of bladder (Ta, T1, or Tis) on TURBT; BCG unresponsive disease (persistent CIS with or without the presence of Ta or T1 tumors within 12 months of completion of BCG, or recurrent high-grade Ta or T1 tumors within 6 months of completion of adequate BCG therapy)
  - NCT: 03317158

**Bridge**
- Criteria: High-grade non-muscle invasive urothelial carcinoma of the bladder; must have all visible papillary tumor resected by the treating urologist at the site registering the patient; no prior intravesical therapy for bladder cancer with the exception of perioperative chemotherapy at the time of TURBT
  - NCT: 05536663

**NEOADJUVANT**
- **EA8192**
  - Criteria: High grade upper tract urothelial carcinoma proven by biopsy with 12 weeks of randomization; no component of small cell/neuroendocrine carcinoma; no evidence of metastatic disease or enlarged LN
  - NCT: 04628767

- **VOLGA**
  - Criteria: Muscle-invasive UC of the bladder; T2-T4aN0/1M0 or UC of the bladder with clinical stage T1N1M0; no prior systemic chemotherapy or immunotherapy for the treatment of MIBC or UC; medically fit for cystectomy; cisplatin ineligible; will receive Enfortumab Vedotin in combination
  - NCT: 04960709

**ADJUVANT**
- **V940-005**
  - Criteria: Muscle-invasive urothelial carcinoma; high-risk pathologic disease after radical resection
  - NCT06305767
BLADDER CANCER

METASTATIC

- **BGB-A317-A3055-101**
  - Criteria: Participants with histologically confirmed advanced or metastatic solid tumors associated with high CCR8 and who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and could not receive any prior therapy targeting CCR8
  - NCT05935098

- **ACR-368-201**
  - Criteria: histologically confirmed, locally advanced (i.e., not amenable to curative surgery and/or radiation therapy) or metastatic cancer that has progressed during or after at least 1 prior therapeutic regimen
  - NCT05548296

- **ASP1012**
  - Criteria: histologically, or cytologically, confirmed diagnosis of locally advanced or metastatic solid tumor
  - NCT06171178

- **OBT076-001**
  - Criteria: Non-curative recurrent and/or metastatic solid tumors for which a standard therapy is not available or is no longer effective; maximum of two prior lines of cytotoxic chemotherapy in the metastatic setting
  - NCT04064359

- **A032001 MAIN-CAV**
  - Criteria: advanced metastatic urothelial cancer of renal pelvis, ureter, bladder, or urethra; prior first-line treatment must have consisted of 4-6 cycles of 1st-line therapy (platinum-based chemo; gem/cis, gem/carbo, MVAC or ddMVAC)
  - NCT05092958

- **NCT05548296**
- **NCT06171178**
- **NCT04064359**
- **NCT05092958**
PROSTATE CANCER

**S1802**
Criteria: Adenocarcinoma of prostate; no prior local therapy for prostate adenocarcinoma; evidence of metastatic disease on bone scan and CT or MRI; received no more than 28 weeks of standard systemic therapy (SST); no progression while on SST; must have surgically resectable disease per urology consult

**NCT: 03678025**

**Xmab®20717**
Criteria: Carcinoma of prostate; progressive mCRPC; progression after treatment with at least 2 prior lines of anticancer therapy approved for treatment of metastatic prostate cancer, subjects who did not have orchiectomy must be on androgen deprivation suppression treatment

**NCT: 05005728**

**ASP1012**
Criteria: histologically, or cytologically, confirmed diagnosis of locally advanced or metastatic solid tumor

**NCT06171178**
KIDNEY CANCER

LOCALLY ADVANCED/METASTATIC

1L

- SLM/Axitinib/Pembrolizumab
  Criteria: histologically and radiologically advanced or metastatic ccRCC; treatment naïve in metastatic setting; CNS mets excluded
  NCT: 05363631

- Keynote03A
  Criteria: histologically confirmed locally advanced/metastatic ccRCC; no prior systemic therapy for advanced RCC, prior neoadjuvant/adjuvant therapy is acceptable if completed ≥12 mo before randomization
  NCT: 04626479

2L+

- NKT2152-101
  Criteria: LA or metastatic ccRCC and progressed during treatment, are R/R and not amenable to curative therapy or standard therapy has progressed during treatment with at least 1 prior line; must take 6 min/400 m walking test; no known symptomatic brain mets; must not need supplemental oxygen or have pulse ox <95% at screening
  NCT: 05119335
KIDNEY CANCER

LOCALLY ADVANCED/METASTATIC

OBT076-001: Criteria: Non-curative recurrent and/or metastatic solid tumors for which a standard therapy is not available or is no longer effective; maximum of two prior lines of cytotoxic chemotherapy in the metastatic setting

AB-2100-201 Criteria: Must have received an immune checkpoint inhibitor and a VEGF-targeted therapy in the advanced or metastatic setting. Must have evidence of progression on or after the last treatment regimen or discontinued treatment for unacceptable toxicity

ASP1012 Criteria: Histologically, or cytologically, confirmed diagnosis of locally advanced or metastatic solid tumor

A031801 Criteria: Histologic or cytologic diagnosis of RCC; at least 1 metastatic bone lesion not treated with prior radiation; no prior cabozantinib; no prior radium-223;

BGB-A317-A3055-101 Criteria: Participants with histologically confirmed advanced or metastatic solid tumors associated with high CCR8 and who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and could not receive any prior therapy targeting CCR8

NCT04064359

NCT06245915

NCT06171178

NCT: 04071223

NCT05935098
Gynecologic Cancer Trials

David P. Bender, MD
Gynecologic Cancer MOG Co-Leader
david-bender@uiowa.edu

Jessica Landgrebe
GynOnc Clinical Research Coordinator
jessica-landgrebe@uiowa.edu

Clinical Trials Hotline: 319-353-8155
OVARIAN CANCER

LOW GRADE SEROUS CARCINOMA

NRG-GY019:
Criteria: Newly diagnosed, stage II-IV low-grade serous ovarian, fallopian tube and primary peritoneal cancers; must have undergone an attempt at maximal upfront cytoreductive surgery, with either optimal (<= 1 cm diameter residual disease/nodule) or suboptimal residual disease (> 1 cm diameter residual disease/nodule) allowed; must enroll within 8 weeks of primary surgery

NCT04095364

HIGH GRADE SEROUS CARCINOMA

GOG-3078-GLORIOSA (Maintenance therapy):
Criteria: Recurrent (1st recurrence), platinum-sensitive high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer; FRα-High; subjects who have not progressed after second-line platinum-based chemotherapy plus bevacizumab; prior PARP required if BRCA mutated; must be randomized within 8 weeks from last dose of platinum-based triplet therapy

NCT05445778
OVARIAN CANCER

**METASTATIC**

- **BGB-A317-A3055-101**
  - Criteria: Participants with histologically confirmed advanced or metastatic solid tumors associated with high CCR8 and who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and could not receive any prior therapy targeting CCR8
  - NCT05538897

- **ACR-368-201**
  - Criteria: histologically confirmed, locally advanced (i.e., not amenable to curative surgery and/or radiation therapy) or metastatic cancer that has progressed during or after at least 1 prior therapeutic regimen
  - NCT05548296

- **P-MUC1C-ALL01-001**
  - Criteria: Must have a confirmed diagnosis of unresectable, locally advanced or metastatic epithelial-derived cancer, refractory to standard of care therapy or ineligible or refused other existing treatment options
  - NCT05239143

- **IMC-F106C-101**: Criteria: HLA-A*02:01 positive; PRAME positive tumor; Relapsed from, refractory to, or intolerant of standard therapies; or, in combination with standard therapies
  - NCT04262466
ENDOMETRIAL CANCER

NEWLY DIAGNOSED HER2+

NRG-GY026:
Criteria: Stage IA-IVB, non-recurrent, chemo-naive, HER2+ endometrial serous carcinoma or endometrial carcinosarcoma; must have myoinvasive disease; must be within 8 weeks of primary surgery (or endometrial biopsy in patients who never undergo hysterectomy) at the time of study registration; no prior radiation therapy, biologic, or targeted therapy for endometrial cancer

NCT05256225

RECURRENT dMMR

NRG-GY025:
Criteria: Recurrent MMR-deficient endometrial cancer; serous and carcinosarcoma subtypes excluded; measurable or detectable disease required; patients may have received up to 2 prior lines of systemic therapy; prior anti-PD1/PD-L1 therapy is allowed if given in combination with chemotherapy or radiation therapy in adjuvant or primary metastatic/recurrent settings; must have had a complete response and have disease progression/relapse with treatment-free interval of 12 months or more from last dose of therapy with immune check inhibition

NCT05112601
ENDOMETRIAL CANCER

NRG-GY028
Criteria: Recurrent/metastatic grade 1 or 2 endometrioid endometrial cancer; measurable disease required; may have received unlimited prior lines of therapy; prior hormonal therapy (e.g., megestrol acetate, medroxyprogesterone acetate, aromatase inhibitor, tamoxifen, fulvestrant) it must have completed at least 6 months prior to registration; no prior AKT inhibitor

ACR-368-201
Criteria: histologically confirmed, locally advanced (i.e., not amenable to curative surgery and/or radiation therapy) or metastatic cancer that has progressed during or after at least 1 prior therapeutic regimen

OBT076-001:
Criteria: Non-curative recurrent and/or metastatic solid tumors for which a standard therapy is not available or is no longer effective; maximum of two prior lines of cytotoxic chemotherapy in the metastatic setting

IMC-F106C-101: Criteria: HLA-A*02:01 positive; PRAME positive tumor; Relapsed from, refractory to, or intolerant of standard therapies; or, in combination with standard therapies

NCT05538897
NCT05548296
NCT04064359
NCT04262466
CERVICAL CANCER

METASTATIC

BT7480-100:
Criteria: Must have a histologically or cytologically confirmed malignant solid tumor associated with Nectin-4 expression

NCT05163041

BGB-A317-A3055-101:
Criteria: Participants with histologically confirmed advanced or metastatic solid tumors associated with high CCR8 and who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and could not receive any prior therapy targeting CCR8

NCT05935098

OPEN

PENDING

ENROLLMENT HOLD
GERM CELL TUMOR

LOW OR STANDARD RISK

AGCT1531:
Criteria: Low risk stage I immature teratoma (IT); site: ovarian; tumor markers: alpha-FP <= 1,000 ng/mL, beta-HCG institutional normal; all ages

Standard risk 2 (SR2)
Site: ovarian; stage: COG stage II and III, FIGO stage IC, II and III; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age < 25

INTERMEDIATE OR POOR RISK

AGCT1532:
Criteria: Histologically or cytologically confirmed germ cell; or Exceptionally raised tumour markers (AFP ≥ 1000ng/mL and/or HCG ≥ 5000 IU/L) without histologic or cytologic confirmation in the rare case where pattern of metastases consistent with GCT, high tumour burden, and a need to start therapy urgently; Primary arising in testis, ovary, retro-peritoneum, or mediastinum; Intermediate or poor prognosis as defined by IGCCC classification

NCT03067181
NCT02582697
BRCA1 OVARIAN CANCER RISK REDUCTION

NRG-CC008:
Criteria: Individuals 35-50 years of age, inclusive; positive CLIA-approved test results for pathogenic or likely pathogenic germline BRCA1 mutation in the patient; non-randomized prospective trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers; patient choice of bilateral salpingectomy or bilateral salpingo-oophorectomy (with or without hysterectomy); no prior radiation to the abdomen/pelvis; no prior hormonal therapy within 90 days

NCT04251052
Head & Neck Cancer Trials

Doug Laux, MD, MS
Head & Neck Cancer MOG Co-Leader
douglas-laux@uiowa.edu

Mimi McKay, MPH, BSN
Clinical Trial Navigator
mariel-mckay@uiowa.edu

Clinical Trials Hotline: 319-353-8155
#### HEAD AND NECK

**HNSCC**

**NEWLY DIAGNOSED ORAL CAVITY**
- **NRG-HN006**
  - Criteria: Pathologically proven diagnosis of SCC of oral cavity including tongue, FOM, mucosal lip, buccal mucosa, lower alveolar ridge, upper alveolar ridge, RMT, or hard palate; T1-2N0M0 AJCC 8th ed; must be candidate for sentinel lymph node biopsy and potential completion neck dissection or elective neck dissection
  - NCT: 04333537

**1L UNRESECTABLE OR METASTATIC**
- **Hookipa**
  - Criteria: HPV 16+ cancer via genotype testing; eligible to receive pembrolizumab
  - NCT: 04180215
- **SGN35-033**
  - Criteria: Metastatic (HNSCC) who have not yet received frontline therapy for metastatic disease and without prior exposure to a PD-1/PD-L1 inhibitor
  - NCT04609566
- **GSK-219885**
  - Criteria: The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx; Subjects must not have had prior systemic therapy administered in the R/M setting
  - NCT06062420

**SALIVARY GLAND**
- **BTCRC-HN17-111**
  - Criteria: LA, recurrent, or metastatic salivary gland carcinoma not amenable to curative surgery or radiation; archival tissue must be available for central confirmation of androgen receptor-positive disease; any number of prior lines permitted but no prior anti-androgen therapy or immune checkpoint blockade permitted
  - NCT: 03942653
HEAD AND NECK

INBRX-106
Criteria: Subjects must have LA or metastatic disease which is checkpoint inhibitor naïve

NCT04198766

TCTLR-101
Criteria: Histologically confirmed SCC regardless of HPV or PD-L1 status; no more than 1 prior line of chemotherapy-based treatment for LA, unresectable, recurrent or metastatic disease; At least 1 lesion that is ≥15 mm in the longest diameter and is safely accessible for intratumoral injection

NCT04799054

BGB-A317-A3055-101
Criteria: Participants with histologically confirmed advanced or metastatic solid tumors associated with high CCR8 and who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and could not receive any prior therapy targeting CCR8

NCT05935098

OPEN

ENROLLMENT HOLD

PENDING
NON-MELANOMA SKIN CANCER

CUTANEOUS SQUAMOUS CELL

TCTLR-101
Criteria: Histologically or cytologically confirmed locally advanced (high-risk) cutaneous squamous cell carcinoma; Patients are eligible for this trial either at initial presentation for cSCC with LA and/or concurrent regional nodal metastasis; At least 1 lesion that ≥15 mm in the longest diameter and is safely accessible for intratumoral injection

NCT04799054

V940-007
Criteria: Has LA Stage II-IV (M0) cSCC without distant metastases; cSCC must be amenable to surgery (resectable) with curative intent

NCT06295809

MERKEL, BASAL, SCC

RPL-001-16
Criteria: Locally advanced or metastatic NMSC not considered treatable by surgery; must have received 8 wks of anti-PD1/PDL1 as their last line of therapy and progressed while on treatment

NCT: 03767348

MERKEL CELL

HCRN MCC20-443
Criteria: Histological or cytological evidence of Merkel cell cancer per AJCC, 8th ed; presence of somatostatin receptors by Ga-68 dotatate imaging; progress on treatment with anti-PD1/L1 administered either as monotherapy or in combination with other check point inhibitors or other therapies

NCT: 05583708
Leukemia Trials

Gerek Sutamtewagul, MD
Leukemia MOG Co-Leader
grek-sutamtewagul@uiowa.edu

Mimi McKay, MPH, BSN
Clinical Trial Navigator
mariel-mckay@uiowa.edu

Clinical Trials Hotline: 319-353-8155
ACUTE MYELOID LEUKEMIA (AML)

**NEWLY DIAGNOSED**

KO-MEN-007  
Criteria: Newly diagnosed or relapsed/refractory AML with NPM1 or KMT2A rearrangement  
NCT: 05735184

**RELAPSED/REFRACTORY**

MKIA-088-001  
A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML  
NCT: 03922100

KO-MEN-007  
Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib or the treatment of patients with acute myeloid leukemia  
NCT: 05735184
MALIGNANT HEME (OTHER)

NEWLY DIAGNOSED MDS
SY-1425-301
Criteria: Must be RARA-positive based on investigational assay; diagnosis of MDS according to WHO classification and classified as very high, high, or intermediate risk per IPSS
NCT: 04797780

CLL
BGB-16673-101
Criteria: Relapsed/Refractory CLL; previously received a covalently binding BTK inhibitor in any line of therapy for ≥8 weeks.
NCT: 05006716

BELLWAVE-011
Criteria: Confirmed diagnosis of CLL/SLL and active disease clearly documented to have a need to initiate therapy; at least 1 marker of disease burden; ability to swallow and retain oral medication
NCT: 06136559

ANY MYELOID MALIGNANCY
CA055-001
Criteria: Moderate or severe hepatic impairment as defined by National Cancer Institute Organ Dysfunction Working Group criteria
NCT: 05209295

OPEN
PENDING
ENROLLMENT HOLD
Lymphoma Trials

**Eric Mou**, MD  
Lymphoma MOG Co-Leader  
[eric-mou@uiowa.edu](mailto:eric-mou@uiowa.edu)

**Mimi McKay**, MPH, BSN  
Clinical Trial Navigator  
[mariel-mckay@uiowa.edu](mailto:mariel-mckay@uiowa.edu)

**Clinical Trials Hotline:** 319-353-8155
LARGE CELL LYMPHOMAS

FRONTLINE

SKYGLO
An Open-Label Study Comparing Glocitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

ANHL1931
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

NCT: 06047080
NCT04759586
NCT01787409
LARGE CELL LYMPHOMAS

RELAPSED/REFRACTORY

- **MC200802**
  - Randomized Phase 2 Study With Safety Run-In of PD-1 Inhibitor and IgG4 SIRPa-Fc Fusion Protein (TTI-622) and PD-1 Inhibitor and IgG1 SIRPa-IgG4-Fc Fusion Protein (TTI-621) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
  - [NCT: 05507541](https://clinicaltrials.gov/ct2/show/NCT05507541)

- **ELM-2**
  - A Study to Assess the Anti-Tumor Activity and Safety of Odonextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated
  - [NCT: 03888105](https://clinicaltrials.gov/ct2/show/NCT03888105)

- **ANTLER**
  - CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
  - [NCT: 04637763](https://clinicaltrials.gov/ct2/show/NCT04637763)

- **CRG-022-101**
  - A Phase 2 Study of CRG-022 in Patients With Relapsed/Refractory Large B-cell Lymphoma
  - [NCT: 05972720](https://clinicaltrials.gov/ct2/show/NCT05972720)

- **MPCT-012L**
  - Study of IMPT-314 (CD19/CD20 bispecific CAR-T) in R/R Aggressive B-cell NHL
  - [NCT: 05826535](https://clinicaltrials.gov/ct2/show/NCT05826535)

- **BGB-16673**
  - A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
  - [NCT: 05006716](https://clinicaltrials.gov/ct2/show/NCT05006716)

- **JNJ-90009530**
  - A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
  - [NCT05784441](https://clinicaltrials.gov/ct2/show/NCT05784441)

- **Pembro + CMP**
  - Pembrolizumab and in-situ injection of CMP-001 in Patients with Relapsed and Refractory Lymphomas
  - Note: Must have a palpable or ultrasound-injectable tumor lesion ≥1 cm.
  - [NCT: 03983668](https://clinicaltrials.gov/ct2/show/NCT03983668)

- **CRG-022-101**
  - A Phase 2 Study of CRG-022 in Patients With Relapsed/Refractory Large B-cell Lymphoma
  - [NCT: 05972720](https://clinicaltrials.gov/ct2/show/NCT05972720)

- **MC200802**
  - Randomized Phase 2 Study With Safety Run-In of PD-1 Inhibitor and IgG4 SIRPa-Fc Fusion Protein (TTI-622) and PD-1 Inhibitor and IgG1 SIRPa-IgG4-Fc Fusion Protein (TTI-621) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
  - [NCT: 05507541](https://clinicaltrials.gov/ct2/show/NCT05507541)
MANTLE CELL LYMPHOMA

FRONTLINE

A052101:
A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients (Age ≥ 70 or ≥ 60 with selected comorbidities) with Mantle Cell Lymphoma

NCT: 05976763
MANTLE CELL LYMPHOMA

RELAPSED/REFRACTORY

ADI-20200101
GLEAN-1: A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (γδ) T Cells in Adults with B Cell Malignancies

NCT: 04735471

BGB-16673
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT: 05006716

Pembro + CMP
Pembrolizumab and in-situ injection of CMP-001 in Patients with Relapsed and Refractory Lymphomas

Note: Must have a palpable or ultrasound-injectable tumor lesion ≥1 cm.

NCT: 03983668
FOLLICULAR LYMPHOMA

RELAPSED/REFRACTORY

Pembro + CMP
Pembrolizumab and in-situ injection of CMP-001 in Patients with Relapsed and Refractory Lymphomas
Note: Must have a palpable or ultrasound-injectable tumor lesion ≥1 cm.
NCT: 03983668

JNJ-90009530
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT05784441

BGB-16673
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
NCT: 05006716

S1608
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIia Follicular Lymphoma
Note: Relapse within 24 months of completing frontline therapy.
NCT: 03269669
CLL/SLL

FRONTLINE

BELLWAVE-011:
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT06136559
CLL/SLL

RELAPSED/REFRACTORY

BGB-16673
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT: 05006716
HODGKIN LYMPHOMA

AHOD2131:
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

NCT05675410
HODGKIN LYMPHOMA

RELAPSED/REFRACTORY

BTCRC HEM 15-027:
Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
NCT03681561

Pembro + CMP
Pembrolizumab and in-situ injection of CMP-001 in Patients with Relapsed and Refractory Lymphomas
Note: Must have a palpable or ultrasound-injectable tumor lesion ≥1 cm.
NCT: 03963668

OPEN

PENDING

ENROLLMENT HOLD
T-CELL LYMPHOMA

FRONTLINE

A051902:
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative (<10%) Peripheral T-Cell Lymphomas

NCT: 04803201

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

NCT01787409
OTHER LYMPHOMAS

Marginal Zone Lymphoma
ELM-2
A Study to Assess the Anti-Tumor Activity and Safety of Odonextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated

Marginal Zone Lymphoma
JNJ-90009530
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Marginal Zone Lymphoma
Pembro + CMP
Pembrolizumab and in-situ injection of CMP-001 in Patients with Relapsed and Refractory Lymphomas
Note: Must have a palpable or ultrasound-injectable tumor lesion ≥1 cm.

Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
BGB-16673
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT: 03888105
NCT05784441
NCT: 03983668
NCT: 05006716
Melanoma Trials

**Mohammed Milhem, MBBS**
Melanoma MOG Co-Leader
mohammed-milhem@uiowa.edu

**Asad Javed, MBBS**
Melanoma MOG Co-Leader
mohammed-milhem@uiowa.edu

**Mimi McKay, MPH, BSN**
Clinical Trial Navigator
mariel-mckay@uiowa.edu

Clinical Trials Hotline: 319-353-8155
**CUTANEOUS MELANOMA**

**NEOADJUVANT**

**NeoDREAM**
Criteria: Stage IIB/IIIC, resectable melanoma, with injectable metastasis (nodal, subcutaneous, cutaneous)
Investigational agent: Neoadjuvant intra-tumoral injection of Daromun Immune therapy

NCT03567889

**TCTLR-101**
Criteria: Resectable melanoma, with injectable metastasis (primary cutaneous or nodal metastasis)
Investigational agent: Neoadjuvant intra-tumoral injection of Toll-like receptor agonists (TLR7/8)

NCT04799054

**ADJUVANT**

**V940-001**
Criteria: Surgically resected diagnosis of Stage IIB or IIIC, III, or IV cutaneous melanoma; has not received any prior systemic therapy for their melanoma beyond surgical resection; no more than 13 weeks have passed between final surgical resection that rendered the participant disease-free and the first dose of pembrolizumab
Investigational Agent: mRNA melanoma neo-antigen vaccine plus Pembrolizumab

NCT05933577
# Cutaneous Melanoma

## Metastatic

<table>
<thead>
<tr>
<th>Study</th>
<th>Criteria</th>
<th>Investigational Agent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cabozantinib + Pembrolizumab</td>
<td>Cutaneous melanoma, unresectable (Stage IIIC and higher). Prior adjuvant immune therapy allowed. Prior BRAF-MEK inhibitor therapy allowed</td>
<td>Tumor-infiltrating lymphocytes (TIL therapy)</td>
</tr>
<tr>
<td>LYL845-101</td>
<td>Cutaneous melanoma refractory to PD1 therapy; Does not require prior BRAF therapy (if the tumor is BRAF V600 mutated. Treated CNS metastasis allowed</td>
<td>Tumor-infiltrating lymphocytes (TIL therapy)</td>
</tr>
<tr>
<td>SGN-BB228-001</td>
<td>Cutaneous melanoma relapsed, refractory, or intolerant to standard of care; must have been previously treated with anti-PD-1 or anti-PD-L1 agents</td>
<td>Bispecific antibody immune therapy drug targeting CD228 and 4-1BB</td>
</tr>
<tr>
<td>MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma</td>
<td>Advanced melanoma patients failing standard of care therapy. Includes uveal and mucosal melanoma cohorts. Successful screening radionucleotide scan required (done on study). Adequate renal and bone marrow function</td>
<td>Lead based, radio-pharmaceutic agent targeting MC1R receptor on melanoma tumor cells</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study ID</th>
<th>NCT03957551</th>
<th>NCT05573095</th>
<th>NCT05571839</th>
<th>NCT05655312</th>
</tr>
</thead>
</table>

---
UVEAL MELANOMA

1L

IDE196-002
Criteria: HLA-A*02:01 negative patients (Testing can be done at U of Iowa)
Treatment naïve patients with metastatic uveal melanoma

Investigational Agent:
Darovasertib + Crizotinib vs investigator choice

NCT05987332
Myeloma Trials

Christopher Strouse, MD
Myeloma MOG Co-Leader
christopher-strouse@uiowa.edu

Mimi McKay, MPH, BSN
Clinical Trial Navigator
mariel-mckay@uiowa.edu

Clinical Trials Hotline: 319-353-8155
MULTIPLE MYELOMA

SMOLDERING MYELOMA

Ecog-Acrin 173
Phase 3 Pre-emptive tx for high risk smoldering myeloma
Dara-Rd x2 years Vs Rd x 2 years

“High Risk” SMM = 2 of these:
- >2.0 g/dl m-protein
- Cyto: +1q, t[4;14], -17p, -13q
- >20% PCs in marrow
- Involved light chains 20x greater than uninvolved Dx in last 1 year, no myeloma defining criteria

NCT: 03937635

NEWLY DIAGNOSED

CARTITUDE-5
Phase 3 comparison of anti-BCMA CAR-T cells in first line
VRd -> Cilta-cel -> no maint Vs VRD -> Rd maintenance
Up to 1 cycle of VRd allowed prior to enrollment (please call us before starting therapy)
Age < 75 years
Transplant deferred OR transplant ineligible patients

NCT: 04923893

S2209
Phase 3 evaluation comparing up front 3 drug regimens with single or double agent maintenance
No prior treatment for MM
Myeloma Frailty Score= frail or intermediate risk regardless of age

NCT05561387

CARTITUDE-2 Cohort G
Phase 2 evaluation of anti-BCMA CAR-T cells in first line
Dara-Rd -> Cilta-cel -> no maint
Up to 2 cycles of Dara-Rd prior to enrollment is allowed (please call us before starting therapy)
Transplant deferred OR transplant ineligible patients

NCT: 04133636

POST SCT

S1803
Phase 3 evaluation of dara maintenance, and MRD based stopping decision
Dara-R vs R maintenance
s/p Auto transplant
Enrollment within 180 days of transplant, and within 1 year of induction therapy

NCT: 04071457
MULTIPLE MYELOMA (CONT’D)

- **Ascorbic Acid + Melphalan**
  - High Dose Ascorbic Acid is hypothesized to have synergy with melphalan. This is a phase 1 dose escalation trial.
  - NCT: 03602235

- **C1071020 – Elranatomab + Carfilzomib / anti-CD47 antibody**
  - Testing combinations with anti-BCMA bispecific antibody.
  - NCT: 05675449

- **P-BCMA-ALLO1**
  - Allogeneic anti-BCMA CAR-T cells.
  - NCT: 04960579

- **QUINTESSENTIAL**
  - Autologous anti-GPRC5d CAR-T cells
  - NCT: 06121843

- **MonumenTAL-8**
  - Combination anti-GPRC5d bispecific antibody + anti-BCMA CAR T cells for high risk myeloma
  - NCT: pending

**RELAPSED/REFRACTORY**

- **Arm 1: Elra + Carf**
  - 1-3 prior lines
  - Prior carfilzomib is OK
  - NCT: 03602235

- **Arm 2: Elra + anti-CD47**
  - 3+ prior lines of therapy
  - Refractory to IMiD, PI, anti-CD38 antibody
  - NCT: 05675449

- **EITHER**
  - 2+ prior lines of therapy
  - Refractory to PI, IMiD, anti-CD38 antibody
  - OR
  - 3+ prior lines of therapy
  - Exposure to PI, IMiD, anti-CD38 antibody

- **3+ prior lines**
  - Prior treatment with anti-BCMA therapy is required
  - NCT: 04960579

**High Risk** myeloma = 1 of:
- Cyto t[4;14, t[14;16], or -17p
- Baseline ISS Stage III
- Extramedullary plasmacytoma
- No prior anti-BCMA therapy
Sarcoma Trials

John Reith, MD
Sarcoma MOG Co-Leader
john-rieth@uiowa.edu

Mimi McKay, MPH, BSN
Clinical Trial Navigator
mariel-mckay@uiowa.edu

Clinical Trials Hotline: 319-353-8155
**LEIOMYOSARCOMA**

- **Polaris**: Grade 2 or 3 LMS STS that would be standardly treated with gem or gem/doc; previous treatment with up to 2 systemic regimens with at least 1 systemic regimen containing doxorubicin.
  - NCT: 05712694

- **TTI-621**: Metastatic or locally advanced leiomyosarcoma not amenable to curative treatment with surgery or radiation; no more than 1 prior treatment regimen for advanced disease which is limited to gem/doc.
  - NCT: 04996004

- **A092104**: Metastatic or locally advanced leiomyosarcoma of uterine origin as established by the site institutional practice; prior progression on, or intolerance to, at least two prior lines of systemic therapy for advanced uLMS, one of which was an anthracycline (monotherapy or combination). Adjuvant therapy will qualify as a prior line of treatment.
  - NCT: 05432791

**UTERINE**

- **GIST**
  - **CGT9486-21-301**: Metastatic or locally advanced leiomyosarcoma of uterine origin as established by the site institutional practice; prior progression on, or intolerance to, at least two prior lines of systemic therapy for advanced disease which is limited to gem/doc.
  - NCT: 05432791

**UNDIFFERENTIATED PLEOMORPHIC**

- **Palbociclib + Pembrolizumab**: Criteria: Any patient with locally advanced, unresectable or undifferentiated pleomorphic sarcoma who has progressed on at least 1 prior line of therapy and for whom pembrolizumab is a next appropriate standard treatment.
  - NCT: 06113809
**SARCOMA**

**AGIOSARCOMA**

**IGNYTE**
Criteria: locally advanced or metastatic disease; at least 1 measurable and injectable lesion; must have received 8 weeks of anti-PD1 as last line of therapy and progressed while on treatment

NCT: 03767348

**CHONDROSARCOMA**

**INBRX-109**
Criteria: Conventional chondrosarcoma, unresectable or metastatic (clear-cell, mesenchymal, extraskeletal myxoid, myxoid, and dedifferentiated chondrosarcoma are not eligible)

NCT: 04950075

OPEN

OPEN

PENDING

PENDING

ENROLLMENT HOLD

ENROLLMENT HOLD
Thoracic Trials

Muhammad Furqan, MD  
Thoracic MOG Co-Leader  
muhammad-furqan@uiowa.edu

Mimi McKay, MPH, BSN  
Clinical Trial Navigator  
mariel-mckay@uiowa.edu

Clinical Trials Hotline: 319-353-8155
NON-SMALL CELL LUNG CANCER

NEGADJUVANT STAGE 1

Ascorbate + Durvalumab
Criteria: Histologically or cytologically confirmed NSCLC; clinical stage I with tumor size > 1cm to 4 cm (T1b, T1c, T2a and N0M0 per AJCC 8th ed); surgically resectable
NCT: 06083454

ADJUVANT STAGE 1

BTCRC-LUN18-153
Criteria: Must have undergone complete surgical resection of stage I NSCLC between 4-12 weeks prior to registration and have negative surgical margins (R0); both squamous and non-squamous histologies aloud; pathological tumor size must be 1.0-4.0cm in greatest dimension
NCT: 04317534

METASTATIC

Avanzar
Criteria: Histologically or cytologically documented NSCLC stage IIIB or IIIC not amenable to surgical resection or definitive chemoradiation or Stage IV metastatic disease; lacks EGFR ALK and ROS1 and no documented tumor genomic alterations in NTRK, BRAF< RET, MET or other actionable driver oncogenes with approved and available therapies
NCT: 05687266

1L

Ipat-Lung
Criteria: Advanced/metastatic NSCLC and have failed or are intolerant to 1st line anti-PD1/PD-L1, either single agent or in combination with chemotherapy and have exhausted/declined or not be candidates for all available SOC therapies
NCT: 04467801

2L
NON-SMALL CELL LUNG CANCER

**METASTATIC, 3rd LINE**

- **SGN35-033**: Criteria: Metastatic NSCLC without known targetable mutations who either a) have not yet received frontline therapy for metastatic disease and without prior exposure to anti PD-1/PD-L1 or b) are relapsed/refractory with progression on anti PD-1/PD therapy. NCT04609566

- **IMC-F106C-101**: Criteria: Relapsed from, refractory to, or intolerant of standard therapies; or, in combination with standard therapies. NCT04262466

- **P-MUC1C-ALLO1-001**: Criteria: Local advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists. NCT05239143

- **INBRX-106**: Criteria: Locally advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists. NCT04198766

- **BGB-A317-A3055-101**: Criteria: Participants with histologically confirmed advanced or metastatic solid tumors associated with high CCR8 and who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and could not receive any prior therapy targeting CCR8. NCT05935098

- **BT7480-100**: Criteria: Must have locally advanced or metastatic disease that is refractory to standard therapy, or for which no standard therapy is judged to be appropriate or provide clinical benefit, as judged by the Investigator. NCT05163041

- **OBT076-001**: Criteria: Subject has received a maximum of two prior lines of cytotoxic chemotherapy in the metastatic setting; subject has tumor that is positive for CD205 antigen by IHC staining. NCT04064359

- **IMC-F106C-101**: Criteria: Relapsed from, refractory to, or intolerant of standard therapies; or, in combination with standard therapies. NCT04262466

- **P-MUC1C-ALLO1-001**: Criteria: Local advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists. NCT05239143

- **INBRX-106**: Criteria: Locally advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists. NCT04198766

- **BGB-A317-A3055-101**: Criteria: Participants with histologically confirmed advanced or metastatic solid tumors associated with high CCR8 and who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and could not receive any prior therapy targeting CCR8. NCT05935098

- **BT7480-100**: Criteria: Must have locally advanced or metastatic disease that is refractory to standard therapy, or for which no standard therapy is judged to be appropriate or provide clinical benefit, as judged by the Investigator. NCT05163041

- **OBT076-001**: Criteria: Subject has received a maximum of two prior lines of cytotoxic chemotherapy in the metastatic setting; subject has tumor that is positive for CD205 antigen by IHC staining. NCT04064359
SMALL CELL LUNG CANCER

1L

MOZART:
Criteria: Extensive disease IV SCLC, or T3-4 disease due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan; No prior systemic therapy for small-cell lung cancer, with the following exceptions: Up to one cycle of platinum doublet chemotherapy with or without durvalumab is allowed up to 4 weeks prior to registration on this study

NCT05903092

M23-385:
Criteria:
Histologically or cytologically confirmed SCLC that is relapsed or refractory (R/R) following at least 1 prior platinum-containing chemotherapy and with no curative therapy available

NCT05599984

2ND LINE+

BGB-A317-A3055-101:
Criteria:
Participants with histologically confirmed advanced or metastatic solid tumors associated with high CCR8 and who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and could not receive any prior therapy targeting CCR8

NCT05935098

BTCRC-LUN20-462
Criteria:
Histologically or cytologically documented diagnosis of extensive stage SCLC and have progressed or recurred after platinum-based chemotherapy with immunotherapy; max of 2 prior lines of systemic therapy in the metastatic setting

NCT: 04919382

2ND LINE+

BGB-A317-A3055-101:
Criteria:
Participants with histologically confirmed advanced or metastatic solid tumors associated with high CCR8 and who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and could not receive any prior therapy targeting CCR8

NCT05935098

BTCRC-LUN20-462
Criteria:
Histologically or cytologically documented diagnosis of extensive stage SCLC and have progressed or recurred after platinum-based chemotherapy with immunotherapy; max of 2 prior lines of systemic therapy in the metastatic setting

NCT: 04919382
Cancer Services – Quad Cities

Shobha Chitneni, MD
Medical Oncologist
shobha-chitneni@uiowa.edu

Mario Sy, MD
Medical Oncologist
mario-sy-1@uiowa.edu

Katy D’Aprile, RN, BSN, OCN
Clinical Trial Coordinator
katherine-daprile@uiowa.edu

Clinical Trials Hotline: 319-353-8155
THORACIC CANCER

NSCLC

S2302: Stage IV or recurrent disease; participants must have received at least one line of anti-PD-1 or anti-PD-L1 therapy for any stage of NSCLC; Participants who received anti-PD-1 or anti-PD-L1 therapy must have had a best stable, partial response or complete response

Criteria: Histologically or cytologically documented diagnosis of extensive stage SCLC and have progressed or recurred after platinum-based chemotherapy with immunotherapy; max of 2 prior lines of systemic therapy in the metastatic setting

Avanzar
Criteria: Stage IIIB or IIIC NSCLC not amenable to surgical resection or definitive chemoradiation or Stage IV metastatic disease; lacks EGFR ALK and ROS1 and no documented tumor genomic alterations in NTRK, BRAF< RET, MET or other actionable driver oncogenes with approved and available therapies

BTCRC-LUN20-462
Criteria: Extensive disease IV SCLC, or T3-4 disease due to multiple lung nodules too extensive or have tumor/nodal volume too large for radiation; No prior systemic therapy with the following exceptions:
- Up to one cycle of platinum doublet chemotherapy +/- durvalumab is allowed up to 4 weeks prior to registration on this study

SCLC

MOZART:
Criteria: Extensive disease IV SCLC, or T3-4 disease due to multiple lung nodules too extensive or have tumor/nodal volume too large for radiation; No prior systemic therapy with the following exceptions:
- Up to one cycle of platinum doublet chemotherapy +/- durvalumab is allowed up to 4 weeks prior to registration on this study

NCT05633602
NCT: 05667266
NCT: 04919382
NCT05020092
BREAST CANCER

TRIPLE NEGATIVE

Optim-ICE: T1cN1-2 or T2-4N0-2; no residual disease or LN after neoadjuvant therapy; neoadjuvant chemo+pembro x 6 cycles; < 12 weeks between surgery and randomization

NCT05812807

ER +

Cambria: must have had definitive locoregional therapy +/- adjuvant systemic therapy; completed at least 2 yrs (but no more than 5) of adjuvant ET (and is still receiving)

NCT05774951

BR009: premenopausal; postoperative pT1-3; ipsilateral nodes pN0 or pN1; if node negative, oncotype DX RS 21-25 or 16-20 with high clinical risk disease; if 1-3 nodes+ oncotype DX RS 26

NCT05879926
GI CANCER

**Colon**

NRG-GI008
Criteria: T1-3, N1/N1c confirmed adenocarcinoma with RO resection; no radiographic evidence of overt metastatic disease; distal extent of tumor ≥12 cm from anal verge on colonoscopy or above peritoneal reflection as documented during surgery or on path specimen; must have had en bloc complete gross resection of tumor (curative resection); microsatellite stable or intact mismatch repair proteins through CLIA approved testing

NCT: 05174169

**GEJ**

A022102
Criteria: Unresectable or metastatic HER2-adenocarcinoma of esophagus, GEJ, or stomach; no prior treatment for unresectable or metastatic disease

NCT05677490
MULTIPLE MYELOMA

**SMOLDERING MYELOMA**

Ecog-Acrin 173
Phase 3 Pro-emptive tx for high risk smoldering myeloma
Dara-Rd x2 years
Vs
Rd x 2 years

“High Risk” SMM = 2 of these:
- >2.0 g/dl m-protein
- Cyto: +1q, t[4;14], -17p, -13q
- >20% PCs in marrow
- Involved light chains 20x greater than uninvolved
Dx in last 1 year, no myeloma defining criteria

NCT: 03837635

**POST SCT**

S1803
Phase 3 evaluation of dara maintenance, and MRD based stopping decision
Dara-R vs R maintenance

s/p Auto transplant

Enrollment within 180 days of transplant, and within 1 year of induction therapy

NCT: 04071457

**NEWLY DIAGNOSED**

S2209
Phase 3 evaluation comparing up front 3 drug regimens with single or double agent maintenance

No prior treatment for MM
Myeloma Frailty Score= frail or intermediate risk regardless of age

NCT05561387

NCT: 03937635

OPEN

PENDING

ENROLLMENT HOLD
LEUKEMIA

ASC2ESCALATE
Criteria: CML-CP, no previous AP or BC

NCT05384587